Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sobi To Start Selling Zynlonta After Sealing EU Approval

High Hopes For Lymphoma Drug

Dec 21 2022

• By Kevin Grogan

Business Growth Concept_1089895325_1200.jpg — Sobi hoping for steady growth from Zynlonta • Source: Shutterstock

Related Content

Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact

Jul 11 2022

Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase

May 01 2021

Related Companies

ADC Therapeutics SA

Swedish Orphan Biovitrum AB

MorphoSys AG

Incyte Corporation

Roche Holding AG

Additional Topics

Approvals Business Strategies Regulation Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window